Patents Examined by Nancy Degen
  • Patent number: 6280721
    Abstract: The invention relates to a method for producing an integrant(s) of Bacillus thuringiensis. The invention further relates to such integrants, compositions comprising such integrants, as well as methods for controlling a pest(s) using these compositions.
    Type: Grant
    Filed: January 25, 1995
    Date of Patent: August 28, 2001
    Assignee: Valent BioSciences, Inc.
    Inventors: Lee Fremont Adams, Michael David Thomas, Alan P. Sloma, William R. Widner, Steen Troels Jørgensen, Per Linå Jørgensen, Børge Krag Diderichsen
  • Patent number: 6242177
    Abstract: The instant invention discloses the unexpected result that mutant signal sequences with reduced translational strength provided essentially complete processing and high levels of expression of a polypeptide of interest as compared to wild type signal sequences, and that many mammalian polypeptides require a narrow range of translation levels to achieve maximum secretion. A set of signal sequence vectors provides a range of translational strengths for optimizing expression of a polypeptide of interest.
    Type: Grant
    Filed: March 1, 1995
    Date of Patent: June 5, 2001
    Assignee: Genentech, Inc.
    Inventors: Laura C. Simmons, Daniel G. Yansura
  • Patent number: 6218357
    Abstract: A fibroin fluid obtained by adding carbon dioxide to a fibroin aqueous solution and then completely removing the carbon dioxide by pressure reduction or heating has fibroin microstructures which are dispersed in a dispersing medium, the fibroin fluid, unlike a conventional fibroin gel, having a fluidity sufficient for bringing it into the sate of a cream, having the property of excellent humidity retention and being widely usable as an agent for decreasing cholesterol or cosmetic.
    Type: Grant
    Filed: August 14, 1997
    Date of Patent: April 17, 2001
    Assignees: Hiroshi Chinzai
    Inventor: Seiji Terauchi
  • Patent number: 6184372
    Abstract: The present invention pertains to a method for treating a patient with a disease in which the levels of interleukin-10 need to be down-regulated which comprises adminstering to the patient a therapeutically effective amount of an antisense oligodeoxynucleotide specific for interleukin-10 mRNA. The present invention also pertains to an antisense oligodeoxynucleotide specific for interleukin-10 mRNA having the formula 5′-TGGGTCTTGGTTCTCAGCTTGGGGCAT (SEQ ID NO:1).
    Type: Grant
    Filed: November 20, 1997
    Date of Patent: February 6, 2001
    Assignee: University of Medicine & Dentistry of New Jersey
    Inventor: Elizabeth S. Raveché
  • Patent number: 6159729
    Abstract: The present invention is directed to a synthetic DNA molecule encoding purified human papillomavirus type 11 L1 protein and derivatives thereof.
    Type: Grant
    Filed: January 26, 1998
    Date of Patent: December 12, 2000
    Assignee: Merck & Co., Ltd.
    Inventors: Kathryn J. Hofmann, Kathrin U. Jansen, Michael P. Neeper, Joseph G. Joyce, Hugh A. George, E. Dale Lehman
  • Patent number: 6150141
    Abstract: The present invention makes available methods and reagents for novel manipulation of nucleic acids. As described herein, the present invention makes use of the ability of intronic sequences, such as derived from group I, group II, or nuclear pre-mRNA introns, to mediate specific cleavage and ligation of discontinuous nucleic acid molecules. For example, novel genes and gene products can be generated by admixing nucleic acid constructs which comprise exon nucleic acid sequences flanked by intron sequences that can direct trans-splicing of the exon sequences to each other. The flanking intronic sequences can, by intermolecular complementation, form a reactive complex which promotes the transesterification reactions necessary to cause the ligation of discontinuous nucleic acid sequences to one another, and thereby generate a recombinant gene comprising the ligated exons.
    Type: Grant
    Filed: March 11, 1997
    Date of Patent: November 21, 2000
    Assignee: Trustees of Boston University
    Inventor: Kevin A. Jarrell
  • Patent number: 6150169
    Abstract: This invention relates to DNA constructs for inserting heterologous gene sequences into a host genome so as to obtain expression of the heterologous gene, to methods of inserting heterologous gene sequences into a host genome, and to organisms carrying modified host genomes. Specifically, the DNA constructs of this invention contain an expression unit of an internal ribosome binding site (IRES) coupled to a heterologous gene sequence. This expression unit is flanked at the 5' and 3' ends by DNA sequences that enable homologous recombination or integration of the construct with the DNA of a targeted host to obtain expression of the heterologous gene in the host.
    Type: Grant
    Filed: January 25, 1996
    Date of Patent: November 21, 2000
    Assignee: The University of Edinburgh
    Inventors: Austin Gerard Smith, Peter Scott Mountford, Richard Frank Lathe
  • Patent number: 6140306
    Abstract: The present invention relates to methods and compositions for treating gram-negative bacterial infections, using BPI protein products. Co-treatment, or concurrent administration, of BPI protein product with an antibiotic in treatment of gram-negative bacterial infections improves the therapeutic effectiveness of the antibiotic, including increasing antibiotic susceptibility of gram-negative bacteria and reversing resistance of the bacteria to antibiotics.
    Type: Grant
    Filed: June 3, 1996
    Date of Patent: October 31, 2000
    Assignee: Xoma Corporation
    Inventors: Lewis H. Lambert, Jr., Roger G. Little, II
  • Patent number: 6140120
    Abstract: Dimerization and oligomerization of proteins are general biological control mechanisms that contribute to the activation of cell membrane receptors, transcription factors, vesicle fusion proteins, and other classes of intra- and extracellular proteins. We have developed a general procedure for the regulated (inducible) dimerization or oligomerization of intracellular proteins. In principle, any two target proteins can be induced to associate by treating the cells or organisms that harbor them with cell permeable, synthetic ligands. To illustrate the practice of this invention, we have induced: (1) the intracellular aggregation of the cytoplasmic tail of the .xi.
    Type: Grant
    Filed: September 16, 1998
    Date of Patent: October 31, 2000
    Assignees: Board of Trustees of Leland Stanford Jr. University, President and Fellows of Harvard College
    Inventors: Gerald R. Crabtree, Stuart L. Schreiber, David M. Spencer, Thomas J. Wandless, Steffan N. Ho, Peter Belshaw
  • Patent number: 6140074
    Abstract: The invention is a protein having the amino acid sequence of Seq. I.D. No. 1 or an allelic variation retaining the biological activity of the protein having the amino acid sequence of Seq. I.D. No. 1, a DNA segment coding for a protein according to claim 1, preferably DNA segment according to claim 2 having the sequence of Seq. I.D. No. 2, or a substitution analog or allelic variation of Seq. I.D. No. 2, a chimeric cell comprising the DNA segment coding for a protein of Seq. I.D. No. 1, preferably a chimeric cell comprising the DNA segment of Seq. I.D. No. 2, a vector comprising a DNA segment coding for a protein having Seq. I.D. No. 1 operably linked to a promoter. The invention provides a preferred vector comprising the following components operably linked from 5' to 3': (a) a promoter; (b) a signal sequence; (c) 5' portion of a highly expressed gene endogenous to a selected host cell, (d) a linker sequence; all preceding the nucleotide sequence coding for TADG5 protein.
    Type: Grant
    Filed: June 9, 1997
    Date of Patent: October 31, 2000
    Inventors: Timothy J. O'Brien, Yinxiang Wang
  • Patent number: 6110666
    Abstract: The invention encompasses a locus control subregion that possesses chromatin opening domain activity, the activity conferring reproducible activation of tissue-specific expression on a linked transgene to a non-physiological level when the transgene is integrated in single copy in the genome of a host cell.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: August 29, 2000
    Assignee: Medical Research Council
    Inventors: Franklin Gerardus Grosveld, James Ellis, Dimitris Kioussis
  • Patent number: 6110459
    Abstract: A method is provided for forming a graft in heart tissue which comprises the transplantation of cells chosen from cardiomyocytes, fibroblasts, smooth muscle cells, endothelial cells and skeletal myoblasts. The grafts are especially useful in treating scar tissue on the heart. Also provided is a method of isolating and culturing cardiomyocytes for use in such grafts.
    Type: Grant
    Filed: May 28, 1997
    Date of Patent: August 29, 2000
    Inventors: Donald A. G. Mickle, Ren-Ke Li, Richard D. Weisel
  • Patent number: 6107078
    Abstract: This invention is directed to improved catalytic compounds, hammerhead ribozymes, capable of hybridizing with a target RNA to be cleaved. These improved compounds have optimized stems (X)m*(X)m', loops (X)b and hybridizing arms. The invention is also directed to compositions for enhanced RNA cleavage which comprise a first synthetic non-naturally occurring oligonucleotide compound which comprises nucleotides whose sequence defines a conserved catalytic region and nucleotides whose sequence is capable of hybridizing with a predetermined target sequence and a second synthetic non-naturally occurring oligonucleotide which does not contain the predetermined target sequence and is complementary to at least a portion of the first oligonucleotide compound. The invention is also directed to synthetic non-naturally occurring oligonucleotide compounds embedded in a tRNA. The ribozymes and compositions of the present invention may be used in vitro or in vivo. They may be used as diagnostic or therapeutic agents.
    Type: Grant
    Filed: May 5, 1997
    Date of Patent: August 22, 2000
    Assignee: Gene Shears Pty Limited
    Inventors: Paul Keese, Marianne Stapper, Rhonda Perriman
  • Patent number: 6100043
    Abstract: Cloning systems useful for the isolation of recombinant nucleic acid are disclosed in which the recombination of cloning-system nucleic acid and foreign nucleic acid is linked to the expression of a moiety on the surface of a host organism, the moiety being a first member of a binding pair. When recombination occurs between the nucleic acid and the foreign nucleic acid, the moiety is expressed on the surface of the host organism. The isolation of recombinant nucleic acid is then performed by attaching a second member of the binding pair to a solid support and contacting the host organism with the support. When the first member of the binding pair is expressed on the surface of the host organism, the host organism binds to the second member of the binding pair attached to the solid support, thereby selectively isolating those organisms.
    Type: Grant
    Filed: January 11, 1996
    Date of Patent: August 8, 2000
    Assignee: The Perkin-Elmer Corporation
    Inventors: John A. Bridgham, John Brandis, John Leong, Paul D. Hoeprich, Jr., Charles L. Sloan, Roger A. O'Neill
  • Patent number: 6090925
    Abstract: Microparticles formed by mixing a macromolecule with a polymer at a pH near the isoelectric point of the macromolecule and incubating the mixture in the presence of an energy source for a predetermined length of time. The microparticles are composed of homogeneously distributed, intertwined macromolecule and polymer. Each microparticle allows aqueous fluids to enter and allows solubilized macromolecule and polymer to exit the microparticle and may be formulated to provide a sustained release of macromolecule and polymer from the interior of the microparticle when placed in an appropriate aqueous medium, such as under physiological conditions. Methods of production and methods of use for research, diagnostics and therapeutics are provided.
    Type: Grant
    Filed: August 19, 1996
    Date of Patent: July 18, 2000
    Assignee: Epic Therapeutics, Inc.
    Inventors: James E. Woiszwillo, Larry R. Brown, Terrence L. Scott, Jie Di, Judith Sudhalter, Charles D. Blizzard
  • Patent number: 6090791
    Abstract: By injecting plasmid DNAs or oligonucleotides with DNA sequence containing a 2 base sequence of unmethylated cytosine and guanine adjacent thereto into mamalian mucosal cells, mucosal immunity and CD4 positive T cells capable of producing interleukin 10 and IFN-.gamma. can be induced.
    Type: Grant
    Filed: July 28, 1998
    Date of Patent: July 18, 2000
    Assignees: Taisho Pharmaceutical Co., Ltd., Yukio Sato
    Inventors: Yukio Sato, Atsushi Irisawa, Ayako Saito, Reiji Kasukawa
  • Patent number: 6087171
    Abstract: A method is provided for inducing DNA synthesis in differentiated neurons. According to certain embodiments of the invention, a method for inducing DNA synthesis in a differentiated neuron is provided that includes obtaining a vector comprising nucleic acid encoding an E2F regulator and/or an E1A regulator, wherein the vector can be used to express the nucleic acid in a differentiated neuron, and transfecting a differentiated neuron with the vector.
    Type: Grant
    Filed: November 18, 1996
    Date of Patent: July 11, 2000
    Assignee: Spinal Cord Society
    Inventors: Toomas Neuman, Kikuo Suda, Howard O. Nornes
  • Patent number: 6087095
    Abstract: The invention is drawn to a method of DNA sequencing using labeled nucleotides that do not act as chain elongation inhibitors where the label is removed or neutralized for the sequential addition of non-labeled nucleotides.
    Type: Grant
    Filed: December 9, 1994
    Date of Patent: July 11, 2000
    Assignee: Medical Research Council
    Inventors: Andre Rosenthal, Sydney Brenner
  • Patent number: 6087094
    Abstract: The present invention generally relates to the field of diagnostic virology. More particularly, the present invention is directed to methods and compositions useful for the detection and differentiation of viral particles and/or virions in specimens. The present invention also provides methods and compositions useful for evaluating the susceptibility of infectious viruses to antiviral agents.
    Type: Grant
    Filed: February 26, 1998
    Date of Patent: July 11, 2000
    Assignees: Diagnostic Hybrids, Inc., Ohio University
    Inventors: David R. Scholl, Joseph D. Jollick
  • Patent number: 6083923
    Abstract: Pharmaceutical compositions comprising sterically stabilized liposomes containing antisense oligonucleotides are provided for the modulation of expression of the human ras gene in both the normal (wildtype) and activated (mutant) forms.
    Type: Grant
    Filed: October 31, 1997
    Date of Patent: July 4, 2000
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: Gregory E. Hardee, Richard S. Geary, Arthur Levin, Michael V. Templin, Randy Howard, Rahul C. Mehta